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with a history of serious gastrointestinal or in‑
tracranial bleeding, known cancer, hemoglo‑
bin levels of less than 9 g/dl, thrombocytope‑
nia (<50 × 103/μl), chronic kidney disease stage 5, 
or potent drug–drug interactions. All patients 
were recruited in outpatient clinics at John 
Paul II Hospital in Kraków, Poland. The study 
protocol was approved by the bioethics com‑
mittee, and all patients gave informed consent 
to participate in the study.
The HAS ‑BLED and CHA2DS2‑VASc scores 
were used to evaluate bleeding and thromboem‑
bolic risk, respectively. Definitions of all comor‑
bidities were derived from our previous study.9 
Major bleeding and clinically relevant nonma‑
jor bleeding (CRNMB) were defined according 
to International Society on Thrombosis and He‑
mostasis criteria.10
Patients were followed on a 6‑month basis 
(a visit at the center or telephone contact). We 
recorded the incidence of ischemic stroke, tran‑
sient ischemic attack, systemic embolism, and 
bleeding. Stroke was diagnosed based on the oc‑
currence of a new and abrupt focal neurologic 
deficit persisting for more than 24 hours and 
confirmed by positive imaging findings. Tran‑
sient ischemic attack was defined as a transient 
episode of neurologic dysfunction caused by fo‑
cal brain, spinal cord, or retinal ischemia, last‑
ing less than 24 hours.
Apart from routine laboratory investiga‑
tions, electrochemiluminescence immunoas‑
says (Roche Diagnostics, Mannheim, Germany) 
were used to measure growth differentiation 
factor 15 (GDF‑15) and N ‑terminal fragment of 
Introduction Non–vitamin K antagonist 
oral anticoagulants (NOACs) are increasing‑
ly used in atrial fibrillation (AF), regardless of 
age, and they are now preferred over vitamin K 
antagonists (VKAs).1 Atrial fibrillation occurs 
in 10% to 17% of the population over 80 years 
old1,2 and increases the risk of ischemic stroke 
at least 4 fold.3
While treating very elderly patients with 
NOACs, it is important to consider several con‑
comitant diseases such as increased risk of falls, 
dementia, chronic kidney disease, and liver dis‑
ease as well as drug–drug interactions to ensure 
the safety of anticoagulation.4
A large global registry showed that 82.3% of 
patients over 85 years with newly diagnosed AF 
receive anticoagulation, of which nearly 46% 
are treated with NOACs,5 most commonly with 
apixaban.6 The current European Society of Car‑
diology guidelines indicate that very elderly pa‑
tients with AF do better on oral anticoagulants 
than not and on NOACs rather than VKAs.7 In el‑
derly patients with AF, safety concerns repre‑
sent the main reason for insufficient use of oral 
anticoagulants.8
The aim of this case series was to evaluate 
the efficacy and safety of apixaban, rivaroxa‑
ban, and dabigatran in real ‑life AF patients aged 
85 years or older, who were followed at a single 
institution on a long ‑term basis.
Methods We enrolled 40 consecutive patients 
over 85 years old, who were diagnosed with non‑
valvular AF and in whom NOAC treatment was 

















S H O R T  C O M M U N I C A T I O N
Efficacy and safety of non–vitamin K antagonist 
oral anticoagulants in very elderly patients with 
atrial fibrillation: a single ‑center experience




S H O R T  C O M M U N I C A T I O N  NOACs in very elderly patients 155
cTnI levels. No significant differences in any of 
the 3 biomarkers were noted between 3 patients 
with thromboembolic events as compared with 
the remainder.
This case series shows acceptable rates of 
ischemic cerebrovascular events as well as ma‑
jor bleeding and CRNMB in patients aged 85 
years or older, who were treated with NOACs. 
The rates of major bleeding were similar to those 
reported in seminal NOAC trials for AF patients 
over the age of 75 years (5.7%/year)11; however, 
stroke or systemic embolism was more common 
in our study (1.7%/year).11 We failed to dem‑
onstrate better safety of apixaban compared 
with rivaroxaban, 15 mg once daily, and dabi‑
gatran, 110 mg twice daily, in very elderly pa‑
tients with AF.
Kim et al13 reported the results for 403 pa‑
tients with AF treated with NOACs at a mean 
(SD) age of 83.4 (3.2) years, who received dab‑
igatran (35%), rivaroxaban (39%), or apixaban 
(26%). They found a similar thromboembolic risk 
(2.4%/year) to that in our study, with a lower risk 
of major and gastrointestinal bleeds (2%/year 
each). Since our patients were older, all above 
85 years, it might be speculated that this dif‑
ference contributes to the higher bleeding risk 
in the current series, together with a low level 
of knowledge on AF and anticoagulation, relat‑
ed in part to cognitive impairment.8
Regarding dosing regimens, the current 
guidelines recommend using reduced ‑dose 
NOACs in elderly patients mainly with im‑
paired renal function.1,5 However, reduced‑
‑dose dabigatran should be used in patients 
older than 80 years, while apixaban, 2.5 mg 
twice daily, is recommended in the presence 
of creatinine levels of 133 μmol/l or higher or 
weight of 60 kg or lower in this elderly popu‑
lation.1 The overrepresentation of AF patients 
on reduced off ‑label doses of NOACs is ob‑
served worldwide, which leads to an increased 
risk of stroke with unaltered bleeding risk.5,12 
In the present study, we did not observe an in‑
crease in embolic events; however, we noted 
a higher risk of bleeding in patients who re‑
ceived too low a dose of apixaban.
Our novel finding is that elevated GDF‑15 
levels at baseline in very elderly patients with 
AF starting NOAC treatment might be useful 
in the prediction of bleeding, which is consistent 
with a study by Hijazi et al,13 although they ana‑
lyzed patients aged 72 years on average. GDF‑15, 
known to be a marker of oxidative stress and 
inflammation, has been shown to be indepen‑
dently associated with bleeding and thrombo‑
embolic events in AF. The current finding, if val‑
idated in a larger group, might help identify pa‑
tients aged 85 years or older who require clos‑
er surveillance.
The  study has several limitations. First, 
the  group was small, but the  findings are 
the prohormone brain natriuretic peptide (NT‑
‑proBNP). ARCHITECT i1000SR (Abbott Lab‑
oratories, Abbott Park, Illinois, United States) 
was used to assess cardiac troponin I (cTnI) 
levels.
Statistical analysis was performed with the 
Statistica 12.5 software (StatSoft, Tulsa, Okla‑
homa, United States). Continuous variables 
were expressed as median (interquartile range 
[IQR]) or mean (SD), while qualitative variables, 
as numbers (percentages). The 2 patient groups 
were compared using the Mann–Whitney test 
or χ2 test or Fisher exact test. A P value of less 
than 0.05 was considered significant.
Results and discussion We enrolled 40 pa‑
tients aged from 85 to 93 years (women, 57.5%). 
Baseline characteristics of patients are present‑
ed in TABLE 1. Three ‑fourths of the study group 
had permanent AF and all patients had a high 
thromboembolic risk. Patients most frequent‑
ly received apixaban (2.5 mg twice daily, 50% of 
patients; 5 mg twice daily, 12.5%), while dabig‑
atran (110 mg twice daily, 20%) or rivaroxaban 
(15 mg/d, 17.5%) were used less commonly. Four‑
teen patients (35%) used an inappropriate NOAC 
dosing regimen, with a predominance of those 
on apixaban, 2.5 mg twice daily (78.5%), instead 
of apixaban, 5 mg twice daily. There were no dif‑
ferences in demographic, clinical, and laboratory 
parameters between patients on apixaban and 
those receiving dabigatran or rivaroxaban (TABLE 1).
During a median follow ‑up of 23.5 months 
(IQR, 20–27 months), 2 strokes (2.5%/year) and 
1 episode of systemic embolism (1.2%/year) were 
reported. Ischemic stroke was reported in 2 pa‑
tients receiving apixaban, 2.5 mg twice daily, in 
the 20th and 17th month of follow ‑up (includ‑
ing 1 patient after discontinuation of NOACs 
while on prophylactic enoxaparin during hos‑
pitalization for pneumonia). Systemic throm‑
boembolism occurred after a 5‑day discontinu‑
ation of apixaban, 5 mg twice daily, due to cat‑
aract surgery. Eight patients died (4%/year), in‑
cluding 5 due to cardiovascular causes (1 death 
from acute pulmonary embolism and 1 from 
acute myocardial infarction on reduced ‑dose 
apixaban). Major bleeds and CRNMB were re‑
ported in 4 patients each (5%/year), includ‑
ing 1 nonfatal intracranial bleeding on dabiga‑
tran, 110 mg twice daily. Four gastrointestinal 
bleeds (5%/year), all on reduced ‑dose apixaban, 
occurred in the first year of follow ‑up without 
coadministration of aspirin. The rates of throm‑
boembolic and bleeding outcomes were similar 
in both treatment groups (TABLE 1).
The concentrations of GDF‑15 were higher in 
8 patients with clinically relevant bleedings as 
compared with the remaining patients (3228 
pg/ml [IQR, 1571–3328 pg/ml] vs 1519 pg/ml 
[IQR, 1075–2560 pg/ml]; P = 0.046). No simi‑
lar differences were noted for NT ‑proBNP and 
KARDIOLOGIA POLSKA 2020; 78 (2)156
might be higher. We did not measure NOAC con‑
centrations, which might have helped optimize 
anticoagulation in high ‑risk groups.15
In conclusion, our single ‑center experience 
supports the use of NOACs as a safe and effec‑
tive anticoagulation treatment in AF patients 
aged 85 years or older.
representative of very elderly Polish patients 
with AF. Secondly, our results could not be re‑
ferred to elderly AF patients with prior major 
bleeds, who were ineligible. Given large differ‑
ences between regions in Poland in terms of an‑
ticoagulation used in AF, which is in part related 
to the type of center,14 the rates in other centers 
TABLE 1 Baseline characteristics and clinical outcomes of the studied patients
Parameter All patients 
(n = 40)




Age, y 86.5 (86–89) 87 (86–89) 86 (85–90) 0.49
Male sex, n (%) 17 (42.5) 13 (52) 4 (26.7) 0.12
Body mass index, kg/m2 24.9 (21.5–26.1) 25.3 (23.7–26.1) 24.1 (20.5–26.3) 0.2
Former smoking, n (%) 16 (40) 12 (48) 4 (26.7) 0.18
Time since AF diagnosis, y 6 (3–14) 5 (3–12) 9 (3–15) 0.32
CHA2DS2‑VASc 6 (5–6) 6 (5–6) 6 (5–6) 0.93
HAS ‑BLED 2 (2–3) 2 (2–3) 2 (2–3) 0.96
Comorbidities, 
n (%)
Diabetes mellitus 18 (45) 12 (48) 6 (40) 0.62
Peripheral arterial 
disease
23 (57.5) 14 (56) 9 (60) 0.8
Chronic kidney disease 28 (70) 16 (64) 12 (80) 0.48
Coronary heart disease 24 (60) 14 (56) 10 (66.7) 0.5
Prior stroke 7 (17.5) 5 (20) 2 (13.3) 0.69
Ulcer disease 4 (10) 3 (12) 1 (6.7) 0.99
Hemoglobin, g/dl 12.9 (1.2) 12.9 (1.2) 12.9 (1.1) 0.93
White blood cells, × 103/µl 6 (5–6.8) 6 (4.9–6.8) 6.2 (5–6.9) 0.58
Fasting blood glucose, mmol/l 6.1 (5.6–6.7) 6.2 (5.7–6.9) 6.1 (5.3–6.5) 0.32
Creatinine clearance, ml/min 50.6 (12.4) 50.6 (12.6) 50.6 (12.6) 0.91
Platelet count, × 103/µl 202.4 (44.8) 200.8 (44.5) 205.1 (46) 0.78
NT ‑proBNP, pg/ml 912 (421–1620) 713 (401–1476) 1193 (545–1992) 0.26
GDF‑15, pg/ml 1654 (1167–3029) 1532 (1141–2030) 2574 (1193–3265) 0.23
cTnI, ng/l 6.8 (5.3–9.4) 7.5 (5.1–9.2) 6.3 (5.4–11) 0.68
Medications, 
n (%)
Statin 26 (65) 17 (68) 9 (60) 0.61
ASA 6 (15) 5 (20) 1 (6.7) 0.38
Proton pump inhibitor 24 (60) 16 (64) 8 (53.3) 0.5
Follow ‑up Duration, mo 23.5 (20–27) 23 (20–26) 25 (19–30) 0.2
Stroke / TIA / systemic 
embolism
3 (7.5) 3 (12) 0 (0) 0.28
Major bleeding / CRNMB 8 (20) 5 (20) 3 (20) 0.99
Death 8 (20) 7 (28) 1 (6.7) 0.22
Cardiovascular death 5 (12.5) 5 (20) 0 (0) 0.38
Data are shown as number (percentage), median (interquartile range) or mean (SD).
Abbreviations: AF, atrial fibrillation; ASA, acetylsalicylic acid, CHA2DS2‑VASc, congestive heart failure, hypertension, age ≥75 years, 
diabetes mellitus, history of stroke or thromboembolism, vascular disease, age 65 to 74 years, female sex; CRNBM, clinically relevant 
non major bleeding; cTnI, cardiac troponin I; GDF‑15, growth differentiation factor 15; HAS ‑BLED, hypertension, abnormal liver function, 
history of stroke or thromboembolism, history of bleeding, age ≥65 years, use of nonsteroidal anti ‑inflammatory drugs, alcohol abuse; 
NT ‑proBNP, N ‑terminal fragment of the prohormone brain natriuretic peptide; TIA, transient ischemic attack
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